Liver transplantation for primary biliary cirrhosis: retrospective analysis of 52 patients in QLTS.
- Author:
Chong-En XU
1
;
Stephen V LYNCH
;
Glenda A BALDERSON
;
Jonathan FAWCETT
;
Russell W STRONG
;
Shinn YEONG
Author Information
- Publication Type:Journal Article
- MeSH: Cyclosporine; therapeutic use; Female; Follow-Up Studies; Graft Rejection; prevention & control; Humans; Liver Cirrhosis, Biliary; surgery; Liver Transplantation; mortality; Male; Middle Aged; Postoperative Period; Retrospective Studies; Secondary Prevention; Survival Rate; Treatment Outcome
- From: Chinese Journal of Hepatology 2004;12(9):543-545
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVERetrospectively analyzing post-transplant primary biliary cirrhosis patients to document the actual survival time, the cause of post-transplant death, and recurrences after liver transplantation in patients followed up by the Queensland Liver Transplant Service (QLTS).
METHODSThe case notes of all post-piggyback liver transplantation patients followed up by QLTS were reviewed. We analyzed the clinical characteristics of the PBC patients, post-transplant actual survival rates, the causes of post-transplant death, and risk factors of recurrence, and compared the survival rates between patients with and without liver transplantation using a European model.
RESULTSFifty-two post-transplant patients with 54 transplantations were identified with an average age of 53 years and a mean follow-up time of 55 months. The actual survival times of PBC patients with grafts for 1 years, 5 years and 10 years were 88.4%, 80.1%, 76.9% and 80.9%, 65.4%, 19.8%. The causes of death were MOF intra-abdominal bleeding, renal failure, sepsis and cardiovascular diseases. Comparing the survival rates between with and without transplantation, 8.5% of PBC patients have recurrences with an average recurrent time of 34 months.
CONCLUSION(1) Liver transplantation could improve survival rates, but the optimum time for transplantation should be focused on; (2) A long-term and larger follow-up sampling should be done to understand the effects of recurrences on patient's long-term survival; (3) CsA may play a more important role in preventing recurrence of PBC than Tacrolimus